In the present study, we investigated the role of p300/CBP in FLT3-ITD AML and aimed to evaluate the therapeutic potential of targeting p300/CBP alone or in combination with FLT3 inhibitors. The gene discussed is FLT3; the disease is acute myeloid leukemia.